You are here:

adalimumab (Humira)

Advice

in the absence of a submission from the holder of the marketing authorisation:

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Drug Details

Drug Name: adalimumab (Humira)
SMC Drug ID: 800/12
Manufacturer: Abbott Laboratories
Indication: Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Non submission
Status: Superseded
Date Advice Published: 9 July 2012

Back